7 Biotechnology Stocks to Buy Now

Advertisement

Seven biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

Northwest Biotherapeutics, Inc. (NWBO) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, NWBO also gets A’s. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

Pharmacyclics, Inc. (PCYC) gets a higher grade this week, advancing from a C last week to a B. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

The rating of Acorda Therapeutics, Inc. (ACOR) moves up this week, rising from a C to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. Shares of ACOR have increased 21.6% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.

This week, Seattle Genetics, Inc. (SGEN) pushes up from a C to a B rating. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. With a price of $53.45, it is above the 50-day moving average of $48.07. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

Amgen’s (AMGN) ratings are looking better this week, moving up to an A from last week’s B. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. At $127.47, the stock is above the 50-day moving average of $120.96. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

BioMarin Pharmaceutical (BMRN) gets a higher grade this week, advancing from a C last week to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. The stock’s price of $81.19 is above the 50-day moving average of $74.12. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/03/7-biotechnology-stocks-to-buy-now-nwbo-pcyc-acor-3/.

©2024 InvestorPlace Media, LLC